<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Recurrent pregnancy loss: Definition and etiology</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Recurrent pregnancy loss: Definition and etiology</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Recurrent pregnancy loss: Definition and etiology</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Togas Tulandi, MD, MHCM, FRCSC, FACOG, FCAHS</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Haya M Al-Fozan, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Charles J Lockwood, MD, MHCM</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kristen Eckler, MD, FACOG</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 24, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Couples with pregnancy loss need empathy and understanding. Early pregnancy loss, especially when recurrent, is an emotionally traumatic experience, similar to that associated with stillbirth or neonatal death.</p><p>Recurrent pregnancy loss (RPL) is one of the most frustrating and difficult areas in reproductive medicine because the etiology is often unknown and there are few evidence-based diagnostic and treatment strategies. Studies on the etiology, evaluation, and management of RPL are often flawed. Common methodologic weaknesses include failure to adhere to generally accepted criteria for RPL, ascertainment bias, improper selection of controls, uneven monitoring of cohorts, no exclusion of aneuploid fetuses, lack of stratification for important factors such as number of previous losses, premature termination of study after interim analysis, and excessive postrandomization patient withdrawal [<a href="#rid1">1</a>].</p><p>In this topic, when discussing study results, we will use the terms "woman/en" or "patient(s)" as they are used in the studies presented. We encourage the reader to consider the specific counseling and treatment needs of transgender and gender diverse individuals.</p><p class="headingAnchor" id="H2"><span class="h1">DEFINITION</span><span class="headingEndMark"> — </span>The definition of RPL varies, which makes studying the phenomenon, and determining which couples to counsel or treat, more challenging. As examples, varying definitions have included:</p><p class="bulletIndent1"><span class="glyph">●</span>Two or more failed clinical pregnancies as documented by ultrasonography or histopathologic examination [<a href="#rid2">2</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Three consecutive pregnancy losses, which are not required to be intrauterine [<a href="#rid3">3,4</a>]. </p><p></p><p>In our practice, we start investigating after two failed clinical pregnancies, including biochemical pregnancies for women undergoing in vitro fertilization. The rationale for including biochemical pregnancies and nonvisualized pregnancies (ectopic pregnancies) in the definition of RPL comes from a retrospective cohort study of 587 women who had three or more consecutive pregnancy losses before 12 weeks gestation [<a href="#rid5">5</a>]. Nonvisualized pregnancy losses (biochemical pregnancy losses and/or pregnancies of unknown location) had the same negative impact on future live birth as an intrauterine pregnancy losses.</p><p>In response to these varied definitions, the European Society of Human Reproduction and Embryology released a 2017 consensus statement proposing that RPL describes two or more pregnancy losses, diagnosed by either serum or urine human chorionic gonadotropin [<a href="#rid6">6</a>]. This diagnosis includes biochemical pregnancies and treated pregnancies of unknown location but does not include confirmed ectopic or molar pregnancies.</p><p>RPL can be further divided into primary or secondary processes [<a href="#rid6">6,7</a>]. Primary RPL refers to pregnancy loss in women who have never carried to viability (24 weeks gestation or beyond). By contrast, secondary RPL refers to pregnancy loss in a woman who has had a previous live birth. The prognosis for successful pregnancy is better with secondary RPL [<a href="#rid7">7</a>].</p><p>There is no specific term for describing women who have had multiple spontaneous miscarriages interspersed with normal pregnancies (ie, nonconsecutive pregnancy losses).</p><p class="headingAnchor" id="H3"><span class="h1">INCIDENCE</span><span class="headingEndMark"> — </span>Approximately 15 percent of pregnant women experience sporadic loss of a clinically recognized pregnancy. Just 2 percent of pregnant women experience two consecutive pregnancy losses and only 0.4 to 1 percent have three consecutive pregnancy losses [<a href="#rid8">8</a>]. The observed frequency of three consecutive pregnancy losses is slightly higher than that expected by chance alone: if the frequency of miscarriage is 15 percent, then the probability of three consecutive miscarriages would be (0.15)(0.15)(0.15), or 0.003 (0.3 percent). By comparison, the observed frequency of two consecutive pregnancy losses is that which would be expected by chance alone (0.15)(0.15) = 0.0225 (2.25 percent).</p><p>These mathematical relationships constitute one basis for defining the disorder, but do not take into account the effect of maternal age or the gestational age at which the miscarriage occurred (see <a class="local">'Definition'</a> above). The prevalence of miscarriage is higher with increasing maternal age  (<a class="graphic graphic_table graphicRef70032" href="/z/d/graphic/70032.html" rel="external">table 1</a>) and at very early gestational ages (eg, at less than 6 weeks of gestation the risk of miscarriage is 22 to 57 percent versus 15 percent at 6 to 10 weeks and 2 to 3 percent after 10 weeks [<a href="#rid9">9</a>]).</p><p class="headingAnchor" id="H4"><span class="h1">RISK FACTORS AND ETIOLOGY</span><span class="headingEndMark"> — </span>Couples who have had a pregnancy loss have two major concerns: the cause and the risk of recurrence. Although RPL is an important problem in women's health, there are many unsolved questions regarding etiology, evaluation, and management. Unfortunately, the cause of RPL can be determined in only 50 percent of patients [<a href="#rid10">10</a>]. General etiological categories of RPL include anatomic, immunological, genetic, endocrine, infectious, thrombophilic, and environmental factors.</p><p class="headingAnchor" id="H5"><span class="h2">Previous pregnancy loss</span><span class="headingEndMark"> — </span>In a first pregnancy, the risk of miscarriage is 11 to 13 percent [<a href="#rid11">11</a>]. After one miscarriage, this rate rises slightly to 14 to 21 percent. After two or three miscarriages, the rate is 24 to 29 percent and 31 to 33 percent, respectively. However, several factors influence these rates:</p><p class="bulletIndent1"><span class="glyph">●</span>The cause of the pregnancy loss impacts the miscarriage risk. As an example, carriers of a 22:22 translocation will almost always miscarry, whereas women with 13:14 translocation have a 25 percent risk.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The gestational age of prior pregnancy loss and interpregnancy interval (IPI) may impact the risk of repeat pregnancy loss. In a secondary analysis of 677 women with a prior pregnancy loss (mean gestational age 8.6±2 weeks), the IPI after a first-trimester loss did not impact the live birth rate in a subsequent pregnancy [<a href="#rid12">12</a>]. However, in a study of women with pregnancy loss between 14 and 19 weeks of gestation (that adjusted for maternal age), an IPI ≤3 months was associated with an increased rate of recurrent loss compared with an IPI of &gt;9 to 12 months (22 versus 11 percent) [<a href="#rid13">13</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Advancing maternal age is associated with a higher rate of pregnancy loss of both normal and abnormal conceptuses [<a href="#rid14">14</a>]. This probably reflects poor oocyte quality in this age group. The increased risk of miscarriage with advancing age was illustrated in a review of over 1 million pregnancies with known outcome and with admission to a hospital [<a href="#rid14">14</a>]. The overall rate of spontaneous pregnancy loss was 11 percent. The approximate rates of clinically recognized miscarriage according to maternal age were: age 20 to 30 years (9 to 17 percent), age 35 (20 percent), age 40 (40 percent), and age 45 (80 percent). (See  <a class="medical medical_review" href="/z/d/html/421.html" rel="external">"Effects of advanced maternal age on pregnancy"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Increasing parity is also associated with an increased rate of miscarriage [<a href="#rid15">15</a>]. This may be partially explained by the correlation between increasing maternal age and greater parity and by "reproductive compensation" (ie, a behavior pattern in which couples make repetitive attempts to bear children after miscarriage) [<a href="#rid16">16</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Previous pregnancy outcome can positively or negatively affect the risk in the next pregnancy. It is generally agreed that the risk of miscarriage increases with each successive pregnancy loss [<a href="#rid17">17</a>], whereas some studies report a pregnancy ending in live birth reduces the risk of miscarriage in the subsequent gestation [<a href="#rid17">17</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Gestational age at the time of pregnancy loss should be considered in determining both the etiology and risk of recurrence. RPL typically occurs at a similar gestational age in consecutive pregnancies [<a href="#rid18">18</a>]. The recurrence risk increases as gestational age at the time of loss increases.</p><p></p><p class="headingAnchor" id="H6"><span class="h2">Uterine factors</span><span class="headingEndMark"> — </span>Acquired and congenital uterine abnormalities are responsible for 10 to 50 percent of RPL [<a href="#rid19">19</a>].</p><p class="headingAnchor" id="H7"><span class="h3">Anomalies</span><span class="headingEndMark"> — </span>Congenital uterine anomalies  (<a class="graphic graphic_figure graphicRef134638" href="/z/d/graphic/134638.html" rel="external">figure 1</a> and <a class="graphic graphic_figure graphicRef134639" href="/z/d/graphic/134639.html" rel="external">figure 2</a>) are present in 10 to 15 percent of women with RPL versus 7 percent of all women [<a href="#rid20">20</a>]. Pregnancy loss may be related to impaired uterine distention or abnormal implantation due to decreased vascularity in a septum, increased inflammation, or reduction in sensitivity to steroid hormones [<a href="#rid21">21</a>].</p><p>The septate uterus is the uterine anomaly associated with the poorest reproductive outcome and the most common uterine abnormality associated with RPL [<a href="#rid22">22</a>]. The fetal survival rate in women with untreated septate uterus is 6 to 28 percent and the miscarriage rate is greater than 60 percent. The longer the septum, the worse the prognosis [<a href="#rid23">23</a>]. However, data on the pregnancy effects of reproductive tract anomalies have been derived from relatively small observational studies that are subject to ascertainment biases.</p><p>The mechanism by which a septate uterus causes pregnancy loss is not clearly understood, but poor blood supply to the septum leading to poor implantation is one possibility [<a href="#rid22">22</a>]. (See  <a class="medical medical_review" href="/z/d/html/5418.html" rel="external">"Congenital uterine anomalies: Clinical manifestations and diagnosis"</a>.)</p><p class="headingAnchor" id="H8"><span class="h3">Leiomyoma</span><span class="headingEndMark"> — </span>Submucous leiomyomas that protrude into the endometrial cavity can impede normal implantation as a result of their position, poor endometrial receptivity of the decidua overlying the myoma, or degeneration with increasing cytokine production  (<a class="graphic graphic_figure graphicRef53241" href="/z/d/graphic/53241.html" rel="external">figure 3</a>) [<a href="#rid24">24</a>]. An association between pregnancy loss and intramural or subserous myomas is less clear, having been demonstrated in some, but not all, studies. </p><p class="headingAnchor" id="H3683147619"><span class="h3">Adenomyosis</span><span class="headingEndMark"> — </span>In a meta-analysis of 15 studies evaluating the effect of adenomyosis on fertility and in vitro fertilization clinical outcomes, the pregnancy loss rate was higher in individuals with adenomyosis than in those without (odds ratio 2.2, 95% CI 1.53-3.15) [<a href="#rid25">25</a>]. Inflammatory changes in the endometrium associated with adenomyosis and/or endometriosis have been postulated as contributing to RPL [<a href="#rid26">26</a>]. Whether one should perform laparoscopy to diagnose endometriosis in women with RPL is not known. </p><p class="headingAnchor" id="H9"><span class="h3">Endometrial polyps</span><span class="headingEndMark"> — </span>There have been no data showing a relationship between endometrial polyps and RPL. Infertility and endometrial polyps is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/5457.html" rel="external">"Endometrial polyps"</a>.)</p><p class="headingAnchor" id="H10"><span class="h3">Intrauterine adhesions</span><span class="headingEndMark"> — </span>Intrauterine adhesions or synechiae lead to pregnancy loss because there is insufficient endometrium to support fetoplacental growth. The main cause of intrauterine adhesions is curettage for pregnancy complications. Curettage of the endometrium, especially within the first four weeks postpartum, traumatizes the basalis layer, which then heals via formation of granulation tissue. Granulating tissue on opposing surfaces of the uterus can eventually fuse and produce tissue bridges, ranging from filmy adhesions composed of endometrial tissue to dense adhesions consisting entirely of connective tissue. The resulting adherence of the uterine walls, with partial or complete obliteration of the uterine cavity, leads to menstrual irregularities (hypomenorrhea, amenorrhea), cyclic pelvic pain, infertility, and RPL. (See  <a class="medical medical_review" href="/z/d/html/3285.html" rel="external">"Intrauterine adhesions: Clinical manifestation and diagnosis"</a>.)</p><p class="headingAnchor" id="H11"><span class="h3">Cervical insufficiency</span><span class="headingEndMark"> — </span>Cervical insufficiency is a cause of recurrent midtrimester, but not early, pregnancy loss. (See  <a class="medical medical_review" href="/z/d/html/6774.html" rel="external">"Cervical insufficiency"</a>.)</p><p class="headingAnchor" id="H12"><span class="h3">Defective endometrial receptivity</span><span class="headingEndMark"> — </span>Estrogen and progesterone prepare the endometrium for pregnancy [<a href="#rid27">27</a>]. Normal endometrial receptivity allows embryo attachment, implantation, invasion, and development of the placenta. These processes are likely to be disturbed when endometrial receptivity is defective, resulting in unexplained infertility and RPL. Causes of defective endometrial receptivity and biomarkers for evaluation of endometrial receptivity are under investigation [<a href="#rid28">28</a>]. One example is a primary endometrial receptor defect [<a href="#rid29">29</a>]. Additional research suggests that RPL is associated with uterine stem cell deficiency and enhanced cellular senescence, which then results in abnormal endometrial preparation for pregnancy that leads to recurrent loss [<a href="#rid30">30</a>]. Clinical tests are not yet available. </p><p class="headingAnchor" id="H13"><span class="h2">Immunologic factors</span><span class="headingEndMark"> — </span>Each step in the establishment of normal pregnancy has been implicated as a possible site of immune-mediated reproductive failure. Both autoimmune and alloimmune mechanisms have been proposed. Since the mechanisms that allow a mother to tolerate her semi-allogeneic conceptus are not well defined, it is difficult to assess the role of aberrant immunologic factors in reproductive failure [<a href="#rid31">31</a>]. (See  <a class="medical medical_review" href="/z/d/html/3966.html" rel="external">"Immunology of the maternal-fetal interface"</a>.)</p><p class="headingAnchor" id="H14"><span class="h3">Antiphospholipid syndrome</span><span class="headingEndMark"> — </span>Several autoimmune diseases have been linked to poor obstetric outcome, but antiphospholipid syndrome (APS) is the only immune condition in which pregnancy loss is a diagnostic criterion for the disease. Five to 15 percent of patients with RPL may have APS [<a href="#rid32">32</a>]. (See  <a class="medical medical_review" href="/z/d/html/6813.html" rel="external">"Antiphospholipid syndrome: Obstetric implications and management in pregnancy"</a>.)</p><p class="headingAnchor" id="H15"><span class="h3">Other immunological factors</span><span class="headingEndMark"> — </span>Allogeneic factors may cause RPL by a mechanism similar to that of graft rejection in transplant recipients. If the blastocyst is developmentally normal and intact, the embryo should be entirely protected by trophoblast cells. However, in some pregnancies, the blastocyst is genetically deformed and not fully intact. As a result, paternally-derived antigens are exposed to the maternal immune system, which leads to a graft rejection response. A secondary immune response would be expected to cause early rejection in cases of recurrent spontaneous abortion. (See  <a class="medical medical_review" href="/z/d/html/3966.html" rel="external">"Immunology of the maternal-fetal interface"</a>.)</p><p>Alternatively, some mothers with RPL may lack essential components of the networks that provide immunological protection to the embryos, such as appropriate expression of complement regulatory proteins (eg, mannose-binding lectin, apoptosis-inducing TNF superfamily members, macrophage inhibitory cytokine 1, Th1/Th2/Th3-type cytokines, and HLA-DR, HLA-G or HLA-E) [<a href="#rid33">33-35</a>]. Dysregulation of the normal immune mechanism probably operates at the maternal-fetal interface and may involve increased activity of uterine natural killer (uNK) cells, which appear to regulate placental and trophoblast growth, local immunomodulation, and control of trophoblast invasion [<a href="#rid36">36,37</a>]. These and other aspects of immunologically-mediated infertility are not well defined.</p><p>A rare immunologically mediated cause of RPL is alloimmunization to blood group antigen P [<a href="#rid38">38</a>]. Cytotoxic IgM or IgG3 antibody directed against the P and PK antigens has been associated with miscarriage in more than 50 percent of affected pregnancies, as well as fetal growth restriction in ongoing pregnancies; the authors speculated that early plasmapheresis could be therapeutic.</p><p>In a large cohort study of 1,513,544 Danish women including 7667 women with multiples sclerosis, pregnancy loss was not significantly related to this autoimmune disorder [<a href="#rid39">39</a>].</p><p class="headingAnchor" id="H16"><span class="h2">Endocrine factors</span><span class="headingEndMark"> — </span>Endocrine factors may account for 15 to 60 percent of RPL.</p><p class="headingAnchor" id="H18"><span class="h3">Diabetes mellitus</span><span class="headingEndMark"> — </span>Although rare, poorly controlled diabetes mellitus is associated with early (and late) pregnancy loss. Several studies have linked high hemoglobin A1C values early in pregnancy (particularly values above 8 percent) to increased frequencies of miscarriage and congenital malformations  (<a class="graphic graphic_figure graphicRef67498" href="/z/d/graphic/67498.html" rel="external">figure 4</a>) [<a href="#rid40">40</a>]. The increased risk in poorly controlled diabetic women is believed to be secondary to hyperglycemia, maternal vascular disease, and possibly immunologic factors. There is no increased risk of miscarriage in women with well-controlled diabetes mellitus [<a href="#rid41">41</a>]. (See  <a class="medical medical_review" href="/z/d/html/94859.html" rel="external">"Pregestational (preexisting) diabetes: Preconception counseling, evaluation, and management"</a>.)</p><p>Insulin resistance, as seen in women with polycystic ovaries, may also be a factor in pregnancy loss. (See <a class="local">'Polycystic ovary syndrome'</a> below.)</p><p class="headingAnchor" id="H19"><span class="h3">Polycystic ovary syndrome</span><span class="headingEndMark"> — </span>The miscarriage rate in women with polycystic ovary syndrome (PCOS) may be as high as 20 to 40 percent, which is higher than the baseline rate in the general obstetric population (10 to 20 percent) [<a href="#rid42">42</a>]. The mechanism for excess pregnancy loss in these patients is unknown, but may be related to elevated serum luteinizing hormone (LH) levels, high testosterone and androstenedione concentrations (which may adversely affect the endometrium), or insulin resistance.</p><p>The sex hormone abnormalities in women with PCOS may cause premature or delayed ovulation, poor endometrial receptivity, and disturbances in synthesis/secretion/action of prostaglandins and ovarian growth factors/cytokines. In one study, a menstrual cycle longer than 34 days, which is common in women with PCOS, was the most important predictor for a RPL [<a href="#rid43">43</a>].</p><p>Women with RPL have a higher prevalence of insulin resistance than fertile controls, whether or not PCOS is present [<a href="#rid44">44</a>]. The role of insulin resistance was suggested in a study showing that treatment of insulin resistance with <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">metformin</a> in women with PCOS was associated with a reduction in pregnancy loss [<a href="#rid45">45</a>]. However, another well-designed trial showed no benefit of metformin compared with <a class="drug drug_general" data-topicid="9281" href="/z/d/drug information/9281.html" rel="external">clomiphene</a> in reducing the incidence of miscarriage, thereby casting doubt about the role of insulin resistance on pregnancy loss [<a href="#rid46">46</a>]. (See  <a class="medical medical_review" href="/z/d/html/7436.html" rel="external">"Clinical manifestations of polycystic ovary syndrome in adults"</a>.)</p><p class="headingAnchor" id="H20"><span class="h3">Thyroid antibodies and disease</span><span class="headingEndMark"> — </span>Some studies have reported an increased rate of fetal loss in women with high serum thyroid antibody concentrations (thyroid peroxidase or thyroglobulin), including those who are euthyroid [<a href="#rid47">47</a>]. Thyroid autoimmunity has also been related to unexplained infertility and implantation failure [<a href="#rid48">48</a>]. Direct evidence of causality, however, is still lacking [<a href="#rid49">49</a>] and conflicting data have also been reported [<a href="#rid50">50</a>]. However, in a randomized trial of 92 euthyroid women with recurrent pregnancy loss and positive for TPO-Ab, <a class="drug drug_general" data-topicid="9557" href="/z/d/drug information/9557.html" rel="external">levothyroxine</a> treatment did not increase the live birth rate [<a href="#rid51">51</a>].</p><p>Poorly controlled thyroid disease (hypo- or hyper-thyroidism) is associated with infertility and pregnancy loss. Excess thyroid hormone increases the risk of miscarriage independent of maternal metabolic dysfunction [<a href="#rid52">52</a>]. (see  <a class="medical medical_review" href="/z/d/html/7851.html" rel="external">"Overview of thyroid disease and pregnancy"</a>). </p><p class="headingAnchor" id="H21"><span class="h3">Hyperprolactinemia</span><span class="headingEndMark"> — </span>Normal circulating levels of prolactin may play an important role in maintaining early pregnancy. This hypothesis was supported by a study of 64 hyperprolactinemic women with RPL randomly assigned to <a class="drug drug_general" data-topicid="9164" href="/z/d/drug information/9164.html" rel="external">bromocriptine</a> therapy or no bromocriptine [<a href="#rid53">53</a>]. Treatment to lower prolactin concentration was associated with a higher rate of successful pregnancy (86 versus 52 percent). Prolactin levels during early pregnancy were significantly greater in women who miscarried. (See  <a class="medical medical_review" href="/z/d/html/6630.html" rel="external">"Management of hyperprolactinemia"</a>.)</p><p class="headingAnchor" id="H320926221"><span class="h3">Luteal phase defect</span><span class="headingEndMark"> — </span>A 2015 Committee Opinion released by the American Society for Reproductive Medicine concluded that "there is no reproducible, pathophysiologically relevant, and clinically practical standard to diagnose luteal phase deficiency and distinguish fertile from infertile women" [<a href="#rid54">54</a>]. The committee concluded that luteal phase deficiency as an independent cause of infertility has not been proven. We do not perform luteal phase testing.</p><p>Progesterone is required for successful implantation and maintenance of pregnancy; therefore, disorders related to impaired progesterone production or action are likely to affect pregnancy success. A defect in corpus luteum function (ie, luteal phase defect) has been hypothesized to be a potential cause of impaired progesterone production and resultant infertility or pregnancy failure. However, it is controversial as to whether such a defect really exists and is related to miscarriage, and there is no consensus on the best method of diagnosis or treatment [<a href="#rid54">54</a>]. </p><p>Several studies have shown that luteal phase defect diagnosed by endometrial biopsy is not predictive of infertility; luteal phase defect has been observed in as many as 25 percent of sequential endometrial biopsies in fertile women. Serum progesterone concentrations are not predictive of pregnancy outcome [<a href="#rid55">55</a>], and there is no high-quality evidence to support the use of exogenous progesterone supplementation to prevent early miscarriage. (See  <a class="medical medical_review" href="/z/d/html/5445.html" rel="external">"Female infertility: Evaluation", section on 'Endometrial biopsy'</a>.)</p><p>Abnormal luteal-phase progesterone production may occur as the result of medical conditions such as elevated prolactin or abnormal thyroid function; women suspected to have one of these disorders are evaluated and treated for the underlying condition [<a href="#rid54">54</a>]. (See <a class="local">'Thyroid antibodies and disease'</a> above and <a class="local">'Hyperprolactinemia'</a> above.)</p><p class="headingAnchor" id="H22"><span class="h2">Genetic factors</span><span class="headingEndMark"> — </span>Abnormalities of chromosome number or structure are the most common cause of sporadic early pregnancy loss, accounting for at least 50 percent of such losses in multiple studies [<a href="#rid56">56</a>]. A significant proportion of RPL may also be associated with structural or numerical chromosomal abnormalities (eg, aneuploidy, mosaicism, translocation, inversion, deletion, fragile sites) [<a href="#rid57">57</a>]. Single-gene, X-linked, or polygenic/multifactorial disorders can also result in sporadic or recurrent miscarriage.</p><p>There appears to be an increased risk of RPL in first degree relatives of women with unexplained RPL [<a href="#rid58">58</a>]. This may be related to shared HLA types, coagulation defects, immune dysfunction, or other undefined heritable factors. </p><p class="headingAnchor" id="H23"><span class="h3">Aneuploidy</span><span class="headingEndMark"> — </span>The risk of aneuploidy increases as the number of previous miscarriages increases [<a href="#rid59">59</a>]. However, a 2020 meta-analysis reported that individuals with sporadic pregnancy loss and RPL had similar percentages of anomalies detected in pregnancy tissue (46 percent) [<a href="#rid60">60</a>]. The relationship between the karyotype of the abortus and risk of RPL requires further study to better define which abnormalities are likely to be recurrent.</p><p>In some series, having one chromosomally abnormal spontaneous abortion appeared to increase the risk of a subsequent loss associated with a chromosomal abnormality [<a href="#rid61">61,62</a>]. As an example, one study reported that the frequency of an abnormal karyotype in a second abortus after a first aneuploid or euploid abortus was 70 and 20 percent, respectively [<a href="#rid61">61</a>]. Another study involving preimplantation genetic testing reported 532 of 764 embryos (70 percent) were abnormal in couples with RPL versus 97 of 215 embryos (45 percent) among controls [<a href="#rid62">62</a>]. In addition, an increased rate of aneuploid embryos has been demonstrated in young women with previous aneuploid conceptions [<a href="#rid63">63</a>].</p><p>However, these findings were not validated in other series [<a href="#rid56">56,64,65</a>]. As an example, in one study, there was no increased risk of chromosome abnormality in the next pregnancy if the prior abortus had a trisomy that was always lethal in utero or when the parental karyotypes were normal [<a href="#rid64">64</a>]. The aneuploid losses in this study, and others, may have been associated, in part, with the older age of the mothers, rather than solely a nonrandom risk in a predisposed couple.</p><p class="headingAnchor" id="H24"><span class="h3">Chromosomal rearrangements</span><span class="headingEndMark"> — </span>Three to 5 percent of couples with RPL have a major chromosomal rearrangement (versus 0.7 percent of the general population); usually a balanced translocation (60 percent reciprocal, 40 percent Robertsonian) or, less commonly, an inversion [<a href="#rid32">32,66</a>]. One or both partners may harbor lethal genes in a heterozygous or balanced combination that does not affect them, but causes pregnancy loss when inherited by the embryo in a homozygous or unbalanced state. Balanced translocations are more common in the female than the male and more likely to result in pregnancy loss if the translocation is of maternal origin. As an example, an X-linked dominant condition may not cause disease or may result in mild disease in a heterozygous female, but can be lethal in males because of the lack of a normal compensatory gene [<a href="#rid32">32</a>]. (See  <a class="medical medical_review" href="/z/d/html/4490.html" rel="external">"Chromosomal translocations, deletions, and inversions"</a>.)</p><p>The likelihood that RPL is related to parental karyotypic abnormality appears to be higher when one or more of the following characteristics are present: young maternal age at second miscarriage, a history of three or more miscarriages, or a history of two or more miscarriages in a sibling or the parents of either partner [<a href="#rid66">66</a>]. A family history of stillbirth or an abnormal liveborn also appear to be risk factors [<a href="#rid24">24</a>]. However, it is important to note that an abnormal parental karyotype, although present, may not be the cause of the RPL; therefore, a complete evaluation of RPL is indicated [<a href="#rid67">67</a>].</p><p class="headingAnchor" id="H25"><span class="h3">Other</span><span class="headingEndMark"> — </span>A meta-analysis of studies evaluating whether there is an association between cytokine polymorphisms and RPL concluded there was either no association or no more than a mild effect [<a href="#rid68">68</a>]. Progesterone receptor gene polymorphisms, as well as other gene polymorphisms, may play a role in RPL [<a href="#rid69">69</a>]. This is an active area of investigation.</p><p>Skewed X-inactivation is associated with increasing maternal age, but does not appear to be associated with RPL [<a href="#rid70">70</a>].</p><p class="headingAnchor" id="H26"><span class="h2">Thrombophilia and fibrinolytic factors</span><span class="headingEndMark"> — </span>Thrombosis of spiral arteries and the intervillous space on the maternal side of the placenta can impair adequate placental perfusion. The resulting abnormalities of the uteroplacental circulation may cause late fetal loss, intrauterine growth restriction, placental abruption, or preeclampsia. A relationship to early pregnancy loss is less clear and may be restricted to specific thrombophilic defects that have not been completely defined, or the presence of multiple defects. There is a large and contradictory literature on the association between maternal inherited thrombophilia and RPL occurring in the first trimester; this is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/4792.html" rel="external">"Inherited thrombophilias in pregnancy"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Impact of common thrombophilias</strong> – A meta-analysis of 89 observational studies reported the following thrombophilias were associated with increased risk of developing RPL when compared with individuals attempting pregnancy who did not have thrombophilia:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Factor V Leiden G1691A mutation – Odds ratio (OR) 2.44, 95% CI 1.96-3.03</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Prothrombin G20210A mutation – OR 2.08, 95% CI 1.61-2.68</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Protein S deficiency – OR 3.45, 95% CI 1.15-10.35</p><p></p><p class="bulletIndent1">Compared with the reference population, antithrombin and protein C deficiencies were not associated with increased risk of RPL. Sensitivity analysis supported these findings. Study imitations included reliance on observational data, inclusion of multiple definitions of RPL, and high heterogeneity of risk estimates [<a href="#rid71">71</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Factor XII deficiency</strong> – A systematic review of the association between fibrinolytic defects and RPL found a significant association for factor XII deficiency (odds ratio 18.11, 95% CI 5.52-59.4, five studies, 1096 women) [<a href="#rid72">72</a>]. There was no significant association with plasminogen activator inhibitor-I 4G/5G polymorphism, increased plasminogen activator inhibitor activity, factor XII C46T polymorphism, or factor XIII polymorphisms. Data on other fibrinolytic defects were sparse. (See  <a class="medical medical_review" href="/z/d/html/1361.html" rel="external">"Overview of the causes of venous thrombosis", section on 'Factor XII deficiency'</a>.)</p><p></p><p>Procoagulant microparticles can also contribute to the hypercoagulable state and thus may interfere with successful implantation and fetal growth. These microparticles were shown to be associated with early and late unexplained pregnancy loss in one pilot study [<a href="#rid73">73</a>]. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Role of placental factors</strong> – Placental mechanisms may play a role in RPL. Some data suggest that expression within the annexin A5 gene (annexin A5 is a placental anticoagulant protein) of the common haplotype M2 is associated with RPL [<a href="#rid74">74,75</a>]. As an example, one study reported that paternal M2 carriage and maternal M2 carriage play a role in RPL [<a href="#rid74">74</a>]. </p><p></p><p class="headingAnchor" id="H27"><span class="h2">Environmental chemicals and stress</span><span class="headingEndMark"> — </span>Although a frequent concern of patients, there is no high-quality evidence showing a relationship between RPL and occupational factors, stress, or low level exposure to most environmental chemicals [<a href="#rid24">24,33</a>]. Chemicals that have been associated with sporadic spontaneous pregnancy loss include anesthetic gases (<a class="drug drug_general" data-topicid="10086" href="/z/d/drug information/10086.html" rel="external">nitrous oxide</a>), arsenic, aniline dyes, benzene, ethylene oxide, formaldehyde, pesticides, lead, mercury, and cadmium [<a href="#rid76">76</a>]. (See  <a class="medical medical_review" href="/z/d/html/5447.html" rel="external">"Overview of occupational and environmental risks to reproduction in females"</a> and  <a class="medical medical_review" href="/z/d/html/4803.html" rel="external">"Cigarette and tobacco products in pregnancy: Impact on pregnancy and the neonate"</a>.)</p><p class="headingAnchor" id="H28"><span class="h2">Other</span></p><p class="headingAnchor" id="H29"><span class="h3">Personal habits</span><span class="headingEndMark"> — </span>The association between RPL and obesity, smoking, alcohol use, and caffeine consumption is unclear [<a href="#rid1">1,77</a>]. These factors may act in a dose-dependent fashion or synergistically to increase the rate of sporadic pregnancy loss. (See  <a class="medical medical_review" href="/z/d/html/5439.html" rel="external">"Pregnancy loss (miscarriage): Terminology, risk factors, and etiology"</a>.)</p><p>Exercise does not appear to increase the rate of sporadic pregnancy loss or RPL [<a href="#rid33">33</a>].</p><p class="headingAnchor" id="H30"><span class="h3">Male factor</span><span class="headingEndMark"> — </span>There is a trend toward repeated miscarriages in women whose male partner has abnormal sperm (eg, fewer than 4 percent normal forms, sperm chromosome aneuploidy) [<a href="#rid78">78,79</a>]. Paternal HLA sharing is not a risk factor for RPL, both maternal HLA allele type may play a role [<a href="#rid1">1</a>]. Advanced paternal age may be a risk factor for miscarriage. (See  <a class="medical medical_review" href="/z/d/html/415.html" rel="external">"Effect of advanced paternal age on fertility and pregnancy"</a>.)</p><p class="headingAnchor" id="H31"><span class="h3">Infection</span><span class="headingEndMark"> — </span>Some infections, such as Listeria monocytogenes, Toxoplasma gondii, cytomegalovirus, and primary genital herpes, are known to cause sporadic pregnancy loss, but no infectious agent has been proven to cause RPL [<a href="#rid33">33</a>]. In one study that attempted to determine the role of infection in miscarriage, chorionic villi from aborted material were analyzed for the presence of Chlamydia trachomatis, Ureaplasma urealyticum, Mycoplasma hominis, cytomegalovirus, adeno-associated virus, and human papillomaviruses (HPV) [<a href="#rid80">80</a>]. The only infections detected were C. trachomatis DNA (detected in one sample) and HPV DNA (detected in eight samples). Karyotype was normal in 54 of 108 samples, abnormal in 38, and could not be determined in 16.</p><p class="headingAnchor" id="H32"><span class="h3">Diminished ovarian reserve</span><span class="headingEndMark"> — </span>Diminished ovarian reserve appears associated with RPL but causation has not been established. A meta-analysis of 15 observational studies including over 3000 patients with RPL reported that more individuals with RPL had evidence of diminished ovarian reserve, specifically low anti-müllerian hormone (AMH) level and low antral follicle count (AFC) compared with those without RPL (AMH: odds ratio [OR] 2.77, 95% CI 1.41-5.46; AFC: OR 2.45, 95% CI 1.16-5.19, respectively) [<a href="#rid81">81</a>].</p><p class="headingAnchor" id="H33"><span class="h3">Celiac disease</span><span class="headingEndMark"> — </span>Untreated celiac disease, even when subclinical, has been associated with pregnancy loss, menstrual disorders, and infertility. Treatment of celiac disease appears to prevent these problems [<a href="#rid82">82,83</a>]. (See  <a class="medical medical_review" href="/z/d/html/4774.html" rel="external">"Epidemiology, pathogenesis, and clinical manifestations of celiac disease in adults"</a>.)</p><p>The relationship between untreated celiac disease and pregnancy loss is not well defined. Although some controlled studies have observed a significant association between poor reproductive performance, including miscarriage, and celiac disease [<a href="#rid84">84</a>], several others have not confirmed this association [<a href="#rid85">85,86</a>]. In addition, no study has proven that celiac disease causes repeated pregnancy loss. Nevertheless, due to the effects of the disease to health in general, and the possible positive effects of treatment of the disease, we suggest screening women with RPL for celiac disease.</p><p class="headingAnchor" id="H34"><span class="h1">EVALUATION AND TREATMENT</span><span class="headingEndMark"> — </span>(See  <a class="medical medical_review" href="/z/d/html/5436.html" rel="external">"Recurrent pregnancy loss: Evaluation"</a> and  <a class="medical medical_review" href="/z/d/html/5444.html" rel="external">"Recurrent pregnancy loss: Management"</a>.)</p><p class="headingAnchor" id="H2683231267"><span class="h1">RESOURCES FOR PATIENTS</span><span class="headingEndMark"> — </span>A <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.acog.org%2Fwomens-health%2Ffaqs%2Frepeated-miscarriages%3Futm_source%3Dhigher-logic%26utm_medium%3Demail%26utm_content%3Djan-25%26utm_campaign%3Dacog2023-digest&amp;token=V2okwtOJYd6RPlhjvFa5asXcwkPk87%2F2G%2Fr%2FyR71Fb%2ByX6TliDmcUHh4ZSQTJ7UKOjtMZjaRzaE9deThjsAM906V%2BQ6hPmmPFwNgbtMPiEHgGUP%2FTZA39f5W3aGFpdcI%2FuffEga3SKKJRTOdAfWxkheNfsvnjq6pgjZpbP7XGqQ%3D&amp;TOPIC_ID=5437" target="_blank">Frequently Asked Questions</a> page for patients is available online through the American College of Obstetricians and Gynecologists. </p><p class="headingAnchor" id="H3400693335"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/114520.html" rel="external">"Society guideline links: Recurrent pregnancy loss"</a>.)</p><p class="headingAnchor" id="H27136041"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.) </p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/z/d/html/85800.html" rel="external">"Patient education: Repeat pregnancy loss (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H1709845942"><span class="h1">PATIENT PERSPECTIVE TOPIC</span><span class="headingEndMark"> — </span>Patient perspectives are provided for selected disorders to help clinicians better understand the patient experience and patient concerns. These narratives may offer insights into patient values and preferences not included in other UpToDate topics. (See  <a class="medical medical_review" href="/z/d/html/132376.html" rel="external">"Patient perspective: Pregnancy loss"</a>.)</p><p class="headingAnchor" id="H35"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definition</strong> – A commonly used definition of recurrent pregnancy loss (RPL) is two or more pregnancy losses, diagnosed by either serum or urine human chorionic gonadotropin, although there are others. This includes pregnancies diagnosed by either serum or urine human chorionic gonadotrophin but excludes confirmed ectopic and molar pregnancies. It may be primary or secondary. (See <a class="local">'Definition'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Incidence</strong> – 0.4 to 1 percent of women have three consecutive pregnancy losses. (See <a class="local">'Incidence'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Common etiologies</strong> </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Chromosomal abnormalities</strong> – Three to 5 percent of couples with RPL have a major chromosomal rearrangement (versus 0.7 percent of the general population); usually a balanced translocation. Recurrent aneuploidy also appears to play a role in RPL. Chromosomal abnormalities are the most common cause of sporadic early pregnancy loss, accounting for at least 50 percent of such losses. (See <a class="local">'Genetic factors'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Uterine abnormalities</strong> – Uterine abnormalities, both acquired (eg, submucosal leiomyoma, intrauterine adhesions) and congenital (eg, septum), have been reported to be responsible for 10 to 50 percent of RPL in small observational studies. (See <a class="local">'Uterine factors'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Antiphospholipid antibody syndrome</strong> – Pregnancy loss is one of the diagnostic criteria for antiphospholipid syndrome. (See <a class="local">'Other immunological factors'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Endocrine factors</strong> – Endocrine factors (eg, poorly controlled diabetes mellitus, elevated thyroid peroxidase or thyroglobulin antibodies, polycystic ovary syndrome, hyperprolactinemia) may account for some cases of RPL. (See <a class="local">'Endocrine factors'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>No causality</strong> – There is no high-quality evidence showing a relationship between RPL and occupational factors, stress, or low level exposure to most environmental chemicals. (See <a class="local">'Environmental chemicals and stress'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Recurrence risk</strong> – RPL typically occurs at a similar gestational age in consecutive pregnancies. The recurrence risk increases as gestational age at the time of loss increases. (See <a class="local">'Previous pregnancy loss'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Christiansen OB, Nybo Andersen AM, Bosch E, et al. Evidence-based investigations and treatments of recurrent pregnancy loss. Fertil Steril 2005; 83:821.</a></li><li><a class="nounderline abstract_t">Practice Committee of the American Society for Reproductive Medicine. Electronic address: <span class="__cf_email__" data-cfemail="38594b4a5578594b4a5516574a5f">[email protected]</span>. Definitions of infertility and recurrent pregnancy loss: a committee opinion. Fertil Steril 2020; 113:533.</a></li><li><a class="nounderline abstract_t">Jauniaux E, Farquharson RG, Christiansen OB, Exalto N. Evidence-based guidelines for the investigation and medical treatment of recurrent miscarriage. Hum Reprod 2006; 21:2216.</a></li><li class="breakAll">Greentop Guideline 17. Recurrent Miscarriage, investigation and treatment of couples. Royal College of Obstetricians and Gynaecologists, 2011.</li><li><a class="nounderline abstract_t">Kolte AM, van Oppenraaij RH, Quenby S, et al. Non-visualized pregnancy losses are prognostically important for unexplained recurrent miscarriage. Hum Reprod 2014; 29:931.</a></li><li><a class="nounderline abstract_t">ESHRE Guideline Group on RPL, Bender Atik R, Christiansen OB, et al. ESHRE guideline: recurrent pregnancy loss. Hum Reprod Open 2018; 2018:hoy004.</a></li><li><a class="nounderline abstract_t">Paukku M, Tulppala M, Puolakkainen M, et al. Lack of association between serum antibodies to Chlamydia trachomatis and a history of recurrent pregnancy loss. Fertil Steril 1999; 72:427.</a></li><li><a class="nounderline abstract_t">Salat-Baroux J. [Recurrent spontaneous abortions]. Reprod Nutr Dev 1988; 28:1555.</a></li><li><a class="nounderline abstract_t">Wilcox AJ, Weinberg CR, O'Connor JF, et al. Incidence of early loss of pregnancy. N Engl J Med 1988; 319:189.</a></li><li><a class="nounderline abstract_t">Abramson J, Stagnaro-Green A. Thyroid antibodies and fetal loss: an evolving story. Thyroid 2001; 11:57.</a></li><li><a class="nounderline abstract_t">Stirrat GM. Recurrent miscarriage. Lancet 1990; 336:673.</a></li><li><a class="nounderline abstract_t">Wong LF, Schliep KC, Silver RM, et al. The effect of a very short interpregnancy interval and pregnancy outcomes following a previous pregnancy loss. Am J Obstet Gynecol 2015; 212:375.e1.</a></li><li><a class="nounderline abstract_t">Roberts CL, Algert CS, Ford JB, et al. Association between interpregnancy interval and the risk of recurrent loss after a midtrimester loss. Hum Reprod 2016; 31:2834.</a></li><li><a class="nounderline abstract_t">Nybo Andersen AM, Wohlfahrt J, Christens P, et al. Maternal age and fetal loss: population based register linkage study. BMJ 2000; 320:1708.</a></li><li><a class="nounderline abstract_t">Khan FH, Alkwai HM, Alshammari RF, et al. Comparison of Fetomaternal Complications in Women of High Parity with Women of Low Parity among Saudi Women. Healthcare (Basel) 2022; 10.</a></li><li><a class="nounderline abstract_t">Sauer MV. Reproduction at an advanced maternal age and maternal health. Fertil Steril 2015; 103:1136.</a></li><li><a class="nounderline abstract_t">Clifford K, Rai R, Regan L. Future pregnancy outcome in unexplained recurrent first trimester miscarriage. Hum Reprod 1997; 12:387.</a></li><li><a class="nounderline abstract_t">Heuser C, Dalton J, Macpherson C, et al. Idiopathic recurrent pregnancy loss recurs at similar gestational ages. Am J Obstet Gynecol 2010; 203:343.e1.</a></li><li class="breakAll">Hill JA. Recurrent pregnancy loss. In: Kistner's Gynecology and Women's Health, 7th ed, Ryan KJ, Berkowitz RS, Barbieri RL, Dunaif A (Eds), Mosby, St. Louis 1999. p.396.</li><li><a class="nounderline abstract_t">Acién P, Acién M, Sánchez-Ferrer M. Complex malformations of the female genital tract. New types and revision of classification. Hum Reprod 2004; 19:2377.</a></li><li><a class="nounderline abstract_t">Devi Wold AS, Pham N, Arici A. Anatomic factors in recurrent pregnancy loss. Semin Reprod Med 2006; 24:25.</a></li><li><a class="nounderline abstract_t">Homer HA, Li TC, Cooke ID. The septate uterus: a review of management and reproductive outcome. Fertil Steril 2000; 73:1.</a></li><li><a class="nounderline abstract_t">Buttram VC Jr, Gibbons WE. Müllerian anomalies: a proposed classification. (An analysis of 144 cases). Fertil Steril 1979; 32:40.</a></li><li><a class="nounderline abstract_t">Simpson JL. Causes of fetal wastage. Clin Obstet Gynecol 2007; 50:10.</a></li><li><a class="nounderline abstract_t">Younes G, Tulandi T. Effects of adenomyosis on in vitro fertilization treatment outcomes: a meta-analysis. Fertil Steril 2017; 108:483.</a></li><li><a class="nounderline abstract_t">Pirtea P, Cicinelli E, De Nola R, et al. Endometrial causes of recurrent pregnancy losses: endometriosis, adenomyosis, and chronic endometritis. Fertil Steril 2021; 115:546.</a></li><li><a class="nounderline abstract_t">Paulson RJ. Hormonal induction of endometrial receptivity. Fertil Steril 2011; 96:530.</a></li><li><a class="nounderline abstract_t">Lessey BA. Assessment of endometrial receptivity. Fertil Steril 2011; 96:522.</a></li><li><a class="nounderline abstract_t">Li TC, Tuckerman EM, Laird SM. Endometrial factors in recurrent miscarriage. Hum Reprod Update 2002; 8:43.</a></li><li><a class="nounderline abstract_t">Lucas ES, Dyer NP, Murakami K, et al. Loss of Endometrial Plasticity in Recurrent Pregnancy Loss. Stem Cells 2016; 34:346.</a></li><li><a class="nounderline abstract_t">Kallen CB, Arici A. Immune testing in fertility practice: truth or deception? Curr Opin Obstet Gynecol 2003; 15:225.</a></li><li><a class="nounderline abstract_t">Reindollar RH. Contemporary issues for spontaneous abortion. Does recurrent abortion exist? Obstet Gynecol Clin North Am 2000; 27:541.</a></li><li><a class="nounderline abstract_t">American College of Obstetricians and Gynecologists. ACOG practice bulletin. Management of recurrent pregnancy loss. Number 24, February 2001. (Replaces Technical Bulletin Number 212, September 1995). American College of Obstetricians and Gynecologists. Int J Gynaecol Obstet 2002; 78:179.</a></li><li><a class="nounderline abstract_t">Kruse C, Steffensen R, Varming K, Christiansen OB. A study of HLA-DR and -DQ alleles in 588 patients and 562 controls confirms that HLA-DRB1*03 is associated with recurrent miscarriage. Hum Reprod 2004; 19:1215.</a></li><li><a class="nounderline abstract_t">Christiansen OB, Nielsen HS, Lund M, et al. Mannose-binding lectin-2 genotypes and recurrent late pregnancy losses. Hum Reprod 2009; 24:291.</a></li><li><a class="nounderline abstract_t">Dosiou C, Giudice LC. Natural killer cells in pregnancy and recurrent pregnancy loss: endocrine and immunologic perspectives. Endocr Rev 2005; 26:44.</a></li><li><a class="nounderline abstract_t">Laird SM, Tuckerman EM, Cork BA, et al. A review of immune cells and molecules in women with recurrent miscarriage. Hum Reprod Update 2003; 9:163.</a></li><li><a class="nounderline abstract_t">Hanafusa N, Noiri E, Yamashita T, et al. Successful treatment by double filtrate plasmapheresis in a pregnant woman with the rare P blood group and a history of multiple early miscarriages. Ther Apher Dial 2006; 10:498.</a></li><li><a class="nounderline abstract_t">Mikkelsen AP, Egerup P, Kolte AM, et al. Pregnancy loss and risk of multiple sclerosis and autoimmune neurological disorder: A nationwide cohort study. PLoS One 2022; 17:e0266203.</a></li><li><a class="nounderline abstract_t">Miller E, Hare JW, Cloherty JP, et al. Elevated maternal hemoglobin A1c in early pregnancy and major congenital anomalies in infants of diabetic mothers. N Engl J Med 1981; 304:1331.</a></li><li><a class="nounderline abstract_t">Mills JL, Simpson JL, Driscoll SG, et al. Incidence of spontaneous abortion among normal women and insulin-dependent diabetic women whose pregnancies were identified within 21 days of conception. N Engl J Med 1988; 319:1617.</a></li><li><a class="nounderline abstract_t">Glueck CJ, Wang P, Goldenberg N, Sieve-Smith L. Pregnancy outcomes among women with polycystic ovary syndrome treated with metformin. Hum Reprod 2002; 17:2858.</a></li><li><a class="nounderline abstract_t">Quenby SM, Farquharson RG. Predicting recurring miscarriage: what is important? Obstet Gynecol 1993; 82:132.</a></li><li><a class="nounderline abstract_t">Craig LB, Ke RW, Kutteh WH. Increased prevalence of insulin resistance in women with a history of recurrent pregnancy loss. Fertil Steril 2002; 78:487.</a></li><li><a class="nounderline abstract_t">Glueck CJ, Phillips H, Cameron D, et al. Continuing metformin throughout pregnancy in women with polycystic ovary syndrome appears to safely reduce first-trimester spontaneous abortion: a pilot study. Fertil Steril 2001; 75:46.</a></li><li><a class="nounderline abstract_t">Legro RS, Barnhart HX, Schlaff WD, et al. Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. N Engl J Med 2007; 356:551.</a></li><li><a class="nounderline abstract_t">Stagnaro-Green A, Glinoer D. Thyroid autoimmunity and the risk of miscarriage. Best Pract Res Clin Endocrinol Metab 2004; 18:167.</a></li><li><a class="nounderline abstract_t">Bellver J, Soares SR, Alvarez C, et al. The role of thrombophilia and thyroid autoimmunity in unexplained infertility, implantation failure and recurrent spontaneous abortion. Hum Reprod 2008; 23:278.</a></li><li><a class="nounderline abstract_t">Matalon ST, Blank M, Ornoy A, Shoenfeld Y. The association between anti-thyroid antibodies and pregnancy loss. Am J Reprod Immunol 2001; 45:72.</a></li><li><a class="nounderline abstract_t">Cleary-Goldman J, Malone FD, Lambert-Messerlian G, et al. Maternal thyroid hypofunction and pregnancy outcome. Obstet Gynecol 2008; 112:85.</a></li><li><a class="nounderline abstract_t">van Dijk MM, Vissenberg R, Fliers E, et al. Levothyroxine in euthyroid thyroid peroxidase antibody positive women with recurrent pregnancy loss (T4LIFE trial): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol 2022; 10:322.</a></li><li><a class="nounderline abstract_t">Anselmo J, Cao D, Karrison T, et al. Fetal loss associated with excess thyroid hormone exposure. JAMA 2004; 292:691.</a></li><li><a class="nounderline abstract_t">Hirahara F, Andoh N, Sawai K, et al. Hyperprolactinemic recurrent miscarriage and results of randomized bromocriptine treatment trials. Fertil Steril 1998; 70:246.</a></li><li><a class="nounderline abstract_t">Practice Committee of the American Society for Reproductive Medicine. Current clinical irrelevance of luteal phase deficiency: a committee opinion. Fertil Steril 2015; 103:e27.</a></li><li><a class="nounderline abstract_t">Ogasawara M, Kajiura S, Katano K, et al. Are serum progesterone levels predictive of recurrent miscarriage in future pregnancies? Fertil Steril 1997; 68:806.</a></li><li><a class="nounderline abstract_t">Stephenson MD, Awartani KA, Robinson WP. Cytogenetic analysis of miscarriages from couples with recurrent miscarriage: a case-control study. Hum Reprod 2002; 17:446.</a></li><li><a class="nounderline abstract_t">Sierra S, Stephenson M. Genetics of recurrent pregnancy loss. Semin Reprod Med 2006; 24:17.</a></li><li><a class="nounderline abstract_t">Christiansen OB, Mathiesen O, Lauritsen JG, Grunnet N. Idiopathic recurrent spontaneous abortion. Evidence of a familial predisposition. Acta Obstet Gynecol Scand 1990; 69:597.</a></li><li><a class="nounderline abstract_t">Bianco K, Caughey AB, Shaffer BL, et al. History of miscarriage and increased incidence of fetal aneuploidy in subsequent pregnancy. Obstet Gynecol 2006; 107:1098.</a></li><li><a class="nounderline abstract_t">Smits MAJ, van Maarle M, Hamer G, et al. Cytogenetic testing of pregnancy loss tissue: a meta-analysis. Reprod Biomed Online 2020; 40:867.</a></li><li><a class="nounderline abstract_t">Hassold TJ. A cytogenetic study of repeated spontaneous abortions. Am J Hum Genet 1980; 32:723.</a></li><li><a class="nounderline abstract_t">Rubio C, Simón C, Vidal F, et al. Chromosomal abnormalities and embryo development in recurrent miscarriage couples. Hum Reprod 2003; 18:182.</a></li><li><a class="nounderline abstract_t">Munné S, Sandalinas M, Magli C, et al. Increased rate of aneuploid embryos in young women with previous aneuploid conceptions. Prenat Diagn 2004; 24:638.</a></li><li><a class="nounderline abstract_t">Warburton D, Kline J, Stein Z, et al. Does the karyotype of a spontaneous abortion predict the karyotype of a subsequent abortion? Evidence from 273 women with two karyotyped spontaneous abortions. Am J Hum Genet 1987; 41:465.</a></li><li><a class="nounderline abstract_t">Sullivan AE, Silver RM, LaCoursiere DY, et al. Recurrent fetal aneuploidy and recurrent miscarriage. Obstet Gynecol 2004; 104:784.</a></li><li><a class="nounderline abstract_t">Franssen MT, Korevaar JC, Leschot NJ, et al. Selective chromosome analysis in couples with two or more miscarriages: case-control study. BMJ 2005; 331:137.</a></li><li><a class="nounderline abstract_t">Goddijn M, Joosten JH, Knegt AC, et al. Clinical relevance of diagnosing structural chromosome abnormalities in couples with repeated miscarriage. Hum Reprod 2004; 19:1013.</a></li><li><a class="nounderline abstract_t">Bombell S, McGuire W. Cytokine polymorphisms in women with recurrent pregnancy loss: meta-analysis. Aust N Z J Obstet Gynaecol 2008; 48:147.</a></li><li><a class="nounderline abstract_t">Bahia W, Finan RR, Al-Mutawa M, et al. Genetic variation in the progesterone receptor gene and susceptibility to recurrent pregnancy loss: a case-control study. BJOG 2018; 125:729.</a></li><li><a class="nounderline abstract_t">Hogge WA, Prosen TL, Lanasa MC, et al. Recurrent spontaneous abortion and skewed X-inactivation: is there an association? Am J Obstet Gynecol 2007; 196:384.e1.</a></li><li><a class="nounderline abstract_t">Liu X, Chen Y, Ye C, et al. Hereditary thrombophilia and recurrent pregnancy loss: a systematic review and meta-analysis. Hum Reprod 2021; 36:1213.</a></li><li><a class="nounderline abstract_t">Sotiriadis A, Makrigiannakis A, Stefos T, et al. Fibrinolytic defects and recurrent miscarriage: a systematic review and meta-analysis. Obstet Gynecol 2007; 109:1146.</a></li><li><a class="nounderline abstract_t">Laude I, Rongières-Bertrand C, Boyer-Neumann C, et al. Circulating procoagulant microparticles in women with unexplained pregnancy loss: a new insight. Thromb Haemost 2001; 85:18.</a></li><li><a class="nounderline abstract_t">Rogenhofer N, Engels L, Bogdanova N, et al. Paternal and maternal carriage of the annexin A5 M2 haplotype are equal risk factors for recurrent pregnancy loss: a pilot study. Fertil Steril 2012; 98:383.</a></li><li><a class="nounderline abstract_t">Karata S, Aydin Y, Ocer F, et al. Hereditary thrombophilia, anti-beta2 glycoprotein 1 IgM, and anti-annexin V antibodies in recurrent pregnancy loss. Am J Reprod Immunol 2012; 67:251.</a></li><li><a class="nounderline abstract_t">Savitz DA, Sonnenfeld NL, Olshan AF. Review of epidemiologic studies of paternal occupational exposure and spontaneous abortion. Am J Ind Med 1994; 25:361.</a></li><li><a class="nounderline abstract_t">Bellver J, Rossal LP, Bosch E, et al. Obesity and the risk of spontaneous abortion after oocyte donation. Fertil Steril 2003; 79:1136.</a></li><li><a class="nounderline abstract_t">Carrell DT, Wilcox AL, Lowy L, et al. Elevated sperm chromosome aneuploidy and apoptosis in patients with unexplained recurrent pregnancy loss. Obstet Gynecol 2003; 101:1229.</a></li><li><a class="nounderline abstract_t">Zidi-Jrah I, Hajlaoui A, Mougou-Zerelli S, et al. Relationship between sperm aneuploidy, sperm DNA integrity, chromatin packaging, traditional semen parameters, and recurrent pregnancy loss. Fertil Steril 2016; 105:58.</a></li><li><a class="nounderline abstract_t">Matovina M, Husnjak K, Milutin N, et al. Possible role of bacterial and viral infections in miscarriages. Fertil Steril 2004; 81:662.</a></li><li><a class="nounderline abstract_t">Bunnewell SJ, Honess ER, Karia AM, et al. Diminished ovarian reserve in recurrent pregnancy loss: a systematic review and meta-analysis. Fertil Steril 2020; 113:818.</a></li><li><a class="nounderline abstract_t">Bustos D, Moret A, Tambutti M, et al. Autoantibodies in Argentine women with recurrent pregnancy loss. Am J Reprod Immunol 2006; 55:201.</a></li><li><a class="nounderline abstract_t">Bradley RJ, Rosen MP. Subfertility and gastrointestinal disease: 'unexplained' is often undiagnosed. Obstet Gynecol Surv 2004; 59:108.</a></li><li><a class="nounderline abstract_t">Kumar A, Meena M, Begum N, et al. Latent celiac disease in reproductive performance of women. Fertil Steril 2011; 95:922.</a></li><li><a class="nounderline abstract_t">Greco L, Veneziano A, Di Donato L, et al. Undiagnosed coeliac disease does not appear to be associated with unfavourable outcome of pregnancy. Gut 2004; 53:149.</a></li><li><a class="nounderline abstract_t">Kotze LM. Gynecologic and obstetric findings related to nutritional status and adherence to a gluten-free diet in Brazilian patients with celiac disease. J Clin Gastroenterol 2004; 38:567.</a></li></ol></div><div id="topicVersionRevision">Topic 5437 Version 48.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15820784" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Evidence-based investigations and treatments of recurrent pregnancy loss.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32115183" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Definitions of infertility and recurrent pregnancy loss: a committee opinion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16707507" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Evidence-based guidelines for the investigation and medical treatment of recurrent miscarriage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16707507" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Evidence-based guidelines for the investigation and medical treatment of recurrent miscarriage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24603132" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Non-visualized pregnancy losses are prognostically important for unexplained recurrent miscarriage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31486805" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : ESHRE guideline: recurrent pregnancy loss.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10519612" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Lack of association between serum antibodies to Chlamydia trachomatis and a history of recurrent pregnancy loss.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3073445" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : [Recurrent spontaneous abortions].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3393170" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Incidence of early loss of pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11272098" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Thyroid antibodies and fetal loss: an evolving story.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1975862" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Recurrent miscarriage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25246378" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : The effect of a very short interpregnancy interval and pregnancy outcomes following a previous pregnancy loss.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27742726" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Association between interpregnancy interval and the risk of recurrent loss after a midtrimester loss.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10864550" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Maternal age and fetal loss: population based register linkage study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36360539" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Comparison of Fetomaternal Complications in Women of High Parity with Women of Low Parity among Saudi Women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25934599" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Reproduction at an advanced maternal age and maternal health.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9070732" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Future pregnancy outcome in unexplained recurrent first trimester miscarriage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20579956" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Idiopathic recurrent pregnancy loss recurs at similar gestational ages.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20579956" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Idiopathic recurrent pregnancy loss recurs at similar gestational ages.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15333604" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Complex malformations of the female genital tract. New types and revision of classification.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16418975" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Anatomic factors in recurrent pregnancy loss.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10632403" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : The septate uterus: a review of management and reproductive outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/456629" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Müllerian anomalies: a proposed classification. (An analysis of 144 cases).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17304022" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Causes of fetal wastage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28865548" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Effects of adenomyosis on in vitro fertilization treatment outcomes: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33581856" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Endometrial causes of recurrent pregnancy losses: endometriosis, adenomyosis, and chronic endometritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21880274" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Hormonal induction of endometrial receptivity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21880273" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Assessment of endometrial receptivity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11866239" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Endometrial factors in recurrent miscarriage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26418742" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Loss of Endometrial Plasticity in Recurrent Pregnancy Loss.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12858110" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Immune testing in fertility practice: truth or deception?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10958002" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Contemporary issues for spontaneous abortion. Does recurrent abortion exist?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12360906" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : ACOG practice bulletin. Management of recurrent pregnancy loss. Number 24, February 2001. (Replaces Technical Bulletin Number 212, September 1995). American College of Obstetricians and Gynecologists.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15070884" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : A study of HLA-DR and -DQ alleles in 588 patients and 562 controls confirms that HLA-DRB1*03 is associated with recurrent miscarriage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18927129" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Mannose-binding lectin-2 genotypes and recurrent late pregnancy losses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15689572" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Natural killer cells in pregnancy and recurrent pregnancy loss: endocrine and immunologic perspectives.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12751778" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : A review of immune cells and molecules in women with recurrent miscarriage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17199881" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Successful treatment by double filtrate plasmapheresis in a pregnant woman with the rare P blood group and a history of multiple early miscarriages.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35358256" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Pregnancy loss and risk of multiple sclerosis and autoimmune neurological disorder: A nationwide cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7012627" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Elevated maternal hemoglobin A1c in early pregnancy and major congenital anomalies in infants of diabetic mothers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3200277" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Incidence of spontaneous abortion among normal women and insulin-dependent diabetic women whose pregnancies were identified within 21 days of conception.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12407039" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Pregnancy outcomes among women with polycystic ovary syndrome treated with metformin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8515913" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Predicting recurring miscarriage: what is important?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12215322" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Increased prevalence of insulin resistance in women with a history of recurrent pregnancy loss.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11163815" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Continuing metformin throughout pregnancy in women with polycystic ovary syndrome appears to safely reduce first-trimester spontaneous abortion: a pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17287476" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15157834" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Thyroid autoimmunity and the risk of miscarriage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18070829" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : The role of thrombophilia and thyroid autoimmunity in unexplained infertility, implantation failure and recurrent spontaneous abortion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11216877" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : The association between anti-thyroid antibodies and pregnancy loss.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18591312" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Maternal thyroid hypofunction and pregnancy outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35298917" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Levothyroxine in euthyroid thyroid peroxidase antibody positive women with recurrent pregnancy loss (T4LIFE trial): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15304465" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Fetal loss associated with excess thyroid hormone exposure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9696215" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Hyperprolactinemic recurrent miscarriage and results of randomized bromocriptine treatment trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25681857" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Current clinical irrelevance of luteal phase deficiency: a committee opinion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9389806" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Are serum progesterone levels predictive of recurrent miscarriage in future pregnancies?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11821293" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Cytogenetic analysis of miscarriages from couples with recurrent miscarriage: a case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16418974" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Genetics of recurrent pregnancy loss.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2094140" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Idiopathic recurrent spontaneous abortion. Evidence of a familial predisposition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16648416" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : History of miscarriage and increased incidence of fetal aneuploidy in subsequent pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32417200" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Cytogenetic testing of pregnancy loss tissue: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7424911" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : A cytogenetic study of repeated spontaneous abortions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12525464" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Chromosomal abnormalities and embryo development in recurrent miscarriage couples.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15305354" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Increased rate of aneuploid embryos in young women with previous aneuploid conceptions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3631080" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Does the karyotype of a spontaneous abortion predict the karyotype of a subsequent abortion? Evidence from 273 women with two karyotyped spontaneous abortions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15458902" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Recurrent fetal aneuploidy and recurrent miscarriage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15985440" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Selective chromosome analysis in couples with two or more miscarriages: case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14990541" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Clinical relevance of diagnosing structural chromosome abnormalities in couples with repeated miscarriage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18366487" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Cytokine polymorphisms in women with recurrent pregnancy loss: meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28972310" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Genetic variation in the progesterone receptor gene and susceptibility to recurrent pregnancy loss: a case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17403428" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Recurrent spontaneous abortion and skewed X-inactivation: is there an association?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33575779" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Hereditary thrombophilia and recurrent pregnancy loss: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17470597" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Fibrinolytic defects and recurrent miscarriage: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11204573" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Circulating procoagulant microparticles in women with unexplained pregnancy loss: a new insight.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22624674" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Paternal and maternal carriage of the annexin A5 M2 haplotype are equal risk factors for recurrent pregnancy loss: a pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22103678" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Hereditary thrombophilia, anti-beta2 glycoprotein 1 IgM, and anti-annexin V antibodies in recurrent pregnancy loss.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8160656" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Review of epidemiologic studies of paternal occupational exposure and spontaneous abortion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12738508" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Obesity and the risk of spontaneous abortion after oocyte donation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12798529" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Elevated sperm chromosome aneuploidy and apoptosis in patients with unexplained recurrent pregnancy loss.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26493117" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Relationship between sperm aneuploidy, sperm DNA integrity, chromatin packaging, traditional semen parameters, and recurrent pregnancy loss.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15037417" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Possible role of bacterial and viral infections in miscarriages.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32145928" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Diminished ovarian reserve in recurrent pregnancy loss: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16451354" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Autoantibodies in Argentine women with recurrent pregnancy loss.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14752299" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Subfertility and gastrointestinal disease: 'unexplained' is often undiagnosed.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21106194" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Latent celiac disease in reproductive performance of women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14684590" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Undiagnosed coeliac disease does not appear to be associated with unfavourable outcome of pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15232359" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Gynecologic and obstetric findings related to nutritional status and adherence to a gluten-free diet in Brazilian patients with celiac disease.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
